RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1

Acta Oncologica

Volumn 54, Issue 8, 2015, Pages 1227-1229

  Kulkarni, Amit A ^a   Boora, Ganesh ^a   Kanwar, Rahul ^a   Ruddy, Kathryn J ^a,b   Banck, Michaela S ^a,b   Le Lindqwister, Nguyet ^c   Therneau, Terry M ^a   Loprinzi, Charles L ^a,b   Beutler, Andreas S ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c Illinois Oncology Research Association CCOP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PACLITAXEL; ANTINEOPLASTIC AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; RSUME PROTEIN, HUMAN; SCLEROPROTEIN; TECTA PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDUCED DISEASE; EXON; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; PACLITAXEL INDUCED PERIPHERAL NEUROPATHY; PERIPHERAL NEUROPATHY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RWDD3 GENE; TECTA GENE; CHEMICALLY INDUCED; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; EXTRACELLULAR MATRIX PROTEINS; GENOTYPE; GPI-LINKED PROTEINS; HUMANS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS;

EID: 84940509229     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.985388     Document Type: Letter

References (9)

1. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011;12:1151-61.
2. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nature Rev Genet 2008;9:356-69.
3. Schneider BP, Li L, Miller K, Flockhart D, Radovich M, Hancock BA, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. 2011 ASCO Annual Meeting Abstracts. 2011. Available from: http://meeting.ascopubs.org/cgi/content/short/29/15-suppl/1000 - otherarticles.
4. Bergmann TK, Vach W, Feddersen S, Eckhoff L, Green H, Herrstedt J, et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 2012;52:871.
5. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 2005;41:1135-9.
6. Beutler AS, Kulkarni AA, Kanwar R, Klein CJ, Therneau TM, Qin R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol 2014;76:727-37.
7. Barnett IJ, Lee S, Lin X. Detecting rare variant effects using extreme phenotype sampling in sequencing association studies. Genet Epidemiol 2013;37:142-51.
8. Li D, Lewinger JP, Gauderman WJ, Murcray CE, Conti D. Using extreme phenotype sampling to identify the rare causal variants of quantitative traits in association studies. Genet Epidemiol 2011;35:790-9.
9. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124.